COMy 2017 | Promising new combinations in the treatment of myeloma
Evangelos Terpos
• 21 Apr 2017
Evangelos Terpos, MD, PhD, from the University of Athens, School of Medicine, Athens, Greece, discusses exciting posters presented at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. One poster presented focused on the combination of lenalidomide, doxorubicin, and dexamethasone as induction therapy before autologous transplantation. One interesting finding from this research was the increased bone formation due to lenalidomide, which hasn’t been found in previous studies. Another interesting poster presented involved the use of lenalidomide and bortezomib as consolidation therapy. This produced very promising results, and may mean that in the future, patients may not require any bone targeted treatment.
